Prague Med. Rep. 2019, 120, 10-17
https://doi.org/10.14712/23362936.2019.6
Is Cardiometabolic Index a Predictive Marker for Renal Cell Cancer Aggressiveness?
References
1. 2012) Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes. Rev. 13(3), 275–286.
< , M., Gunn, P., Gibson, S. (https://doi.org/10.1111/j.1467-789X.2011.00952.x>
2. 2001) Obesity and renal cell cancer – a quantitative review. Br. J. Cancer 85, 984–990.
< , A., Hsieh, C. C., Lindblad, P., Lu, C. M., Cook, N. R., Wolk, A. (https://doi.org/10.1054/bjoc.2001.2040>
<PubMed>
3. 2007) Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int. J. Immunopathol. Pharmacol. 20, 37–46.
< , M. R., Ippoliti, F. (https://doi.org/10.1177/039463200702000105>
4. 2008) Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am. J. Cardiol. 102, 424–428.
< , A., Laclaustra, M., León, M., Casasnovas, J. A., Grima, A., Luengo, E., Ordoñez, B., Bergua, C., Bes, M., Pascual, I., Alegría, E.; MESYAS Registry Investigators (https://doi.org/10.1016/j.amjcard.2008.03.079>
5. 2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17(6), 1471–1474.
< , S. B., Compton, C. C. (https://doi.org/10.1245/s10434-010-0985-4>
6. 2002) Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 287, 356–359.
< , E. S., Giles, W. H., Dietz, W. H. (https://doi.org/10.1001/jama.287.3.356>
7. 1997) Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96, 2520–2525.
< , J. M., Hennekens, C. H., O’Donnell, C. J., Breslow, J. L., Buring, J. E. (https://doi.org/10.1161/01.CIR.96.8.2520>
8. 2013) Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac. J. Cancer Prev. 14, 243–248.
< , Y. Z., Pan, L., Du, C. J., Ren, D. Q., Xie, X. M. (https://doi.org/10.7314/APJCP.2013.14.1.243>
9. 2013) Metabolic factors associated with risk of renal cell carcinoma. PLoS One 8(2), e57475.
< , C., Rapp, K., Stocks, T., Manjer, J. Bjørge, T., Ulmer, H., Engeland, A., Almqvist, M., Concin, H., Selmer, R., Ljungberg, B., Tretli, S., Nagel, G., Hallmans, G., Jonsson, H., Stattin, P. (https://doi.org/10.1371/journal.pone.0057475>
<PubMed>
10. 2015) Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. Eur. J. Cancer 51(18), 2747–2758.
< , A. V., Pasupuleti, V., Benites-Zapata, V. A., Thota, P., Deshpande, A., Perez-Lopez, F. R. (https://doi.org/10.1016/j.ejca.2015.08.031>
11. 2008) Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 38, 106–111.
< , A., Ito, K., Sumitomo, M., Kimura, F., Asano, T., Hayakawa, M. (https://doi.org/10.1093/jjco/hym158>
12. 1999) Do people with similar waist circumference share similar health risks irrespective of height? Tohoku J. Exp. Med. 188, 55–60.
< , S. D., Yoshinaga, H. (https://doi.org/10.1620/tjem.188.55>
13. 2010) Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11, 11–18.
< , M. M. (https://doi.org/10.1111/j.1467-789X.2009.00623.x>
14. 2009) Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur. J. Cancer Prev. 18, 240–247.
< , M., Noda, M., Kurahashi, N., Iwasaki, M., Sasazuki, S., Iso, H., Tsugane, S. (https://doi.org/10.1097/CEJ.0b013e3283240460>
15. 1997) Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler. Thromb. Vasc. Biol. 17, 1114–1120.
< , J., Hein, H. O., Suadicani, P., Gyntelberg, F. (https://doi.org/10.1161/01.ATV.17.6.1114>
16. 2007) Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin. Cancer Res. 13(2 Pt 2), 685s–692s.
< , J., Libermann, T. A. (https://doi.org/10.1158/1078-0432.CCR-06-1867>
17. 2008) Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J. Clin. Epidemiol. 61, 646–653.
< , C. M., Huxley, R. R., Wildman, R. P., Woodward, M. (https://doi.org/10.1016/j.jclinepi.2007.08.012>
18. 2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67(5), 913–924.
< , B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., Mulders, P., Powles, T., Staehler, M., Volpe, A., Bex, A. (https://doi.org/10.1016/j.eururo.2015.01.005>
19. 2009) Validating the waist-height ratio and developing centiles for use amongst children and adolescents. Acta Paediatr. 98(1), 148–152.
< , S., Truby, H., Abbott, R. A., Davies, P. S. W. (https://doi.org/10.1111/j.1651-2227.2008.01050.x>
20. 2013) Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome. Asian Pac. J. Cancer Prev. 14(12), 7351–7354.
< , E., Otunctemur, A., Sahin, S., Dursun, M., Besiroglu, H., Koklu, I., Polat, E. C., Erkoc, M., Danis, E., Bozkurt, M. (https://doi.org/10.7314/APJCP.2013.14.12.7351>
21. 2014) Association between the metabolic syndrome and high tumor grade and stage of primary urothelial cell carcinoma of the bladder. Asian Pac. J. Cancer Prev. 15, 1447–1451.
< , E., Otunctemur, A., Dursun, M., Koklu, I., Sahin, S., Besiroglu, H., Erkoc, M., Danis, E., Bozkurt, M. (https://doi.org/10.7314/APJCP.2014.15.3.1447>
22. 2004) The changing evolution of renal tumours: a single center experience over a two-decade period. Eur. Urol. 45, 490–493.
< , J. J., Tazi, H., Bensalah, K., Rodriguez, A., Vincendeau, S., Rioux-Leclercq, N., Guillé, F., Lobel, B. (https://doi.org/10.1016/j.eururo.2003.12.015>
23. 2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am. J. Epidemiol. 161, 147–152.
< , C., Patel, A. V., Mondul, A. M., Jacobs, E. J., Thun, M. J., Calle, E. E. (https://doi.org/10.1093/aje/kwh334>
24. 1999) Pathology of renal cell carcinoma: recent developments. Clin. Oncol. (R. Coll. Radiol.) 11, 263–268.
< , J. H. (https://doi.org/10.1053/clon.1999.9060>
25. 2012) The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int. J. Cancer 130, 2118–2128.
< , M., Garmo, H., Hammar, N., Jungner, I., Walldius, G., Lambe, M., Holmberg, L. (https://doi.org/10.1002/ijc.26212>
26. 2015) The “cardiometabolic index” as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin. Chim. Acta 438, 274–278.
< , I., Daimon, T. (https://doi.org/10.1016/j.cca.2014.08.042>
27. 2012) Serum lipids and the risk of gastrointestinal malignancies in the Swedish AMORIS study. J. Cancer Epidemiol. 2012, 792034.
< , W., Garmo, H., Holmberg, L., Hammar, N., Jungner, I., Walldius, G., Van Hemelrijck, M. (https://doi.org/10.1155/2012/792034>
<PubMed>
28. 2018) Association of body mass index with mortality and postoperative survival in renal cell cancer patients, a meta-analysis. Oncotarget 9(17), 13959–13970.
, J., Chen, Q., Li, Z. M., Xu, X. D., Song, A. F., Wang, L. S. (
29. 2013) Visceral obesity and risk of high grade disease in clinical T1a renal cell carcinoma. J. Urol. 189(2), 447–453.
< , Y., Wang, H. K., Zhang, H. L., Yao, X. D., Zhang, S. L., Dai, B., Shen, Y. J., Liu, X. H., Zhou, L. P., Ye, D. W. (https://doi.org/10.1016/j.juro.2012.09.030>